Global
Prenatal and New-born Genetic Testing Market: Snapshot
Prenatal
and new-born genetic tests refer to the systematic diagnostic tests
and screenings undertaken to determine the risk of certain genetic
disorders in newborn children and fetuses in stages as early as eight
to ten weeks of gestation. The use of a variety of screening and
diagnostic tools for detecting chromosomal abnormalities and the risk
of diseases such as Patau syndrome, Down syndrome, and Edward
syndrome is increasing at a significant pace across the world.
The
vast rise in prevalence of genetic abnormalities and late pregnancies
are some of the key factors to have led to an increased demand for
prenatal and new-born genetic tests across the globe. The vast
advancements observed in diagnostic and screening technologies and
the rise in awareness about genetic diseases are also considered
crucial to the rising demand for genetic tests in children, both
before and after birth. Transparency Market Research states that the
market will exhibit a remarkable 26.9% CAGR over the report’s
forecast period.
Browse
Market Research
Report:
http://www.transparencymarketresearch.com/prenatal-new-born-genetic-testing.html
http://www.transparencymarketresearch.com/prenatal-new-born-genetic-testing.html
Emerging
Markets to Present Most Lucrative Growth Opportunities
Presently,
North America is the dominant market for the global prenatal and
newborn genetic testing market, accounting for a massive chunk of the
overall market. Apart from a large pool of highly-aware parents and a
rising prevalence of genetic disorders in the region, the large
number of companies operating in the diagnostics as well as screening
sectors have also helped the prenatal and newborn genetic testing
market strengthen its foothold in the region. Another developed
region, Europe, is also a mature market for prenatal and newborn
genetic testing.
However,
in the next few years, the prenatal and newborn genetic testing
market will witness the most traction across emerging regional
markets such as Asia Pacific, and Middle East and Africa. The vast
untapped opportunities in these regions and an encouraging rise in
awareness about genetic testing, rising affordability, and increasing
prevalence of genetic diseases will together contribute towards the
healthy growth of the prenatal and newborn genetic testing market in
these regions in the near future.
Some
of the key vendors operating in the diagnostics field of prenatal and
newborn genetic testing are Ariosa Diagnostics, Bio-Rad Laboratories,
Perkin Elmer, and Agilent Technologies. Key vendors operating in the
screening segment of prenatal and newborn genetic testing are
Verinata Health and Sequenom, Inc.
Fill
the form for an exclusive sample of this report:
No comments:
Post a Comment